The combination of AMBRA1 and loricrin expression represents an independent prognostic biomarker in non-ulcerated AJCC Stage I and II melanoma, which can stratify patients at a low risk of disease recurrence [151]. This evidence concerns the gene AMBRA1 and melanoma.